<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>miR-101-3p &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/mir-101-3p/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 13 Jan 2026 13:56:54 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>miR-101-3p &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>METTL14-Regulated miR-101-3p Boosts NSCLC Drug Sensitivity</title>
		<link>https://bioengineer.org/mettl14-regulated-mir-101-3p-boosts-nsclc-drug-sensitivity/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 13 Jan 2026 13:56:33 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Exosomal miRNA]]></category>
		<category><![CDATA[Gefitinib sensitivity]]></category>
		<category><![CDATA[İşte bu içerik için 5 uygun etiket (virgülle ayrılmış): **Exosomal microRNA]]></category>
		<category><![CDATA[METTL14]]></category>
		<category><![CDATA[METTL14 regulation]]></category>
		<category><![CDATA[miR-101-3p]]></category>
		<category><![CDATA[NSCLC therapy]]></category>
		<category><![CDATA[NSCLC therapy** **Kısa açıklama:** 1. **METTL14 regulation:** Makalenin temel mekanizması (miR-101-3p'nin METTL14 tarafından dü]]></category>
		<guid isPermaLink="false">https://bioengineer.org/mettl14-regulated-mir-101-3p-boosts-nsclc-drug-sensitivity/</guid>

					<description><![CDATA[In the relentless pursuit of precision oncology, recent findings have illuminated a compelling molecular mechanism that could redefine treatment paradigms for non-small cell lung cancer (NSCLC), particularly concerning the widely used therapeutic agent Gefitinib. A groundbreaking study led by Kong, Wu, Li, and colleagues provides robust insight into how the intracellular and exosomal microRNA miR-101-3p, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">316503</post-id>	</item>
	</channel>
</rss>
